Liquidia Technologies (NASDAQ: LQDA) generated approximately $130 million in first-quarter 2026 sales for its flagship therapy, Yutrepia. Nearly 1,000 prescribing physicians have adopted the pulmonary arterial hypertension (PAH) treatment since its 2025 launch. Zacks highlighted these results in a detailed analysis published July 22, 2026.
The company is advancing L606, an investigational treprostinil formulation, as a primary future growth driver. This pipeline development targets further expansion within the PAH market.
Liquidia shares have surged 134.6% year-to-date following the strong commercial performance. The company continues to compete against established industry players including United Therapeutics and J&J.